Lupin Q4 PAT Surges 89 Percent to Rs 1460 Crore Revenue Up 33 Percent

Lupin Q4 results for FY26 announced on 7 May 2026 delivered an outstanding performance with consolidated net income rising 89% year on year to Rs 1,460.4 crore. The Lupin Q4 revenue from operations grew 33% to Rs 7,391.9 crore, driven by exceptional North America generics performance with sales surging 55% year on year to Rs 3,514.5 crore. The Lupin Q4 EBITDA expanded 68% to Rs 2,171.1 crore reflecting strong operating leverage.

Investors tracking Lupin Q4 results FY26 will note that North America contributed Rs 3,514.5 crore in revenue, followed by India at Rs 1,908.2 crore growing 12% year on year. The Lupin Q4 highlights include the successful US launch of Dapagliflozin tablets, the generic of Farxiga, and a tentative approval for Sugammadex injection, the generic of Bridion, representing significant commercial opportunities.

Get Free Stock Recommendations on Univest

Lupin Q4 FY26 Results at a Glance

Track live financials and analyst ratings on the Univest Screener.

Key Highlights from Lupin Q4 FY26

North America Surge Drives Revenue Outperformance

The Lupin Q4 North America revenue surged 55% year on year to Rs 3,514.5 crore, driven by complex generics launches, volume share gains in existing products, and the commercial success of newly approved molecules. The Lupin Q4 North America performance was supported by the successful launch of generic Dapagliflozin tablets, a high-value diabetes medication with significant addressable market in the US generics space.

India Business Steady at 12 Percent Growth

The Lupin Q4 India business grew 12% year on year to Rs 1,908.2 crore, with cardiovascular, respiratory, diabetology, and GI therapeutic segments contributing broad-based growth. The Lupin Q4 India performance reflects the company’s strong field force and brand equity in key doctor segments, and aligns with the broader branded generics market growth in India.

Complex Generics Pipeline and New Approvals

The Lupin Q4 results were supported by a robust pipeline of complex generics and specialty products receiving US FDA approvals. The Lupin Q4 period included a tentative approval for Sugammadex injection, the generic of Bridion used for anaesthesia reversal, which represents a significant commercial opportunity once the exclusivity period clears. The Lupin Q4 pipeline of respiratory, ophthalmology, and dermatology complex generics provides multi-year revenue visibility.

Risks to Monitor

• US price erosion: Generic drug price erosion in North America can compress Lupin Q4 realisations on its existing product portfolio, even as volumes grow.
• Regulatory risk: US FDA warning letters or import alerts at manufacturing sites could disrupt Lupin Q4 product approvals and shipments.
• Competition in gDapagliflozin: Increasing competition from other generic entrants in Dapagliflozin could reduce market share and pricing over time.
• India branded generics competition: Competition from MNCs and domestic pharma peers in key therapeutic segments creates pricing pressure on Lupin Q4 India business.

Conclusion

The Lupin Q4 results FY26 confirm a breakout year with PAT up 89% to Rs 1,460.4 crore and revenue up 33% to Rs 7,391.9 crore, powered by North America generics outperformance. The Lupin Q4 results validate the company’s multi-year R and D investment in complex generics that are now generating commercial returns.

For FY27, the most important variable for Lupin Q4 investors is whether North America revenue growth sustains above 20% through new complex generics launches, and whether the India business can re-accelerate from 12% to 15% growth through new product launches and therapy segment expansion.

Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.

Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

What was the Lupin Q4 FY26 PAT?

Lupin Q4 FY26 consolidated net income was Rs 1,460.4 crore, up 89% year on year, driven by North America generics surge of 55% and operating leverage with EBITDA growing 68% to Rs 2,171 crore.

What is the Lupin Q4 FY26 revenue?

Lupin Q4 FY26 consolidated revenue from operations was Rs 7,391.9 crore, up 33% year on year. North America contributed Rs 3,514.5 crore up 55% and India contributed Rs 1,908.2 crore up 12%.

What drove Lupin Q4 North America growth?

Lupin Q4 North America revenue surged 55% driven by the launch of generic Dapagliflozin tablets, volume share gains in existing generics, and the scale-up of complex generics in respiratory, dermatology, and other therapeutic areas.

What new products did Lupin receive approval for in Q4?

Lupin Q4 received a tentative approval for Sugammadex injection, the generic of Bridion for anaesthesia reversal. The company also launched generic Dapagliflozin during the quarter, and secured US FDA approval for generic Liraglutide.

What is Lupin Q4 FY27 outlook?

Lupin Q4 FY27 depends on sustaining North America complex generics momentum, India business re-acceleration, and successful commercialisation of the tentatively approved Sugammadex injection once exclusivity clears.

Recent Article

Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026